Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China

Clinical Infectious Diseases

Volumn 50, Issue 2, 2010, Pages 264-271

  Ma, Ye ^a   Zhao, Decai ^a   Yu, Lan ^a   Bulterys, Marc ^b   Robinson, Matthew L ^a,c   Zhao, Yan ^a   Dou, Zhihui ^a   Chiliade, Philippe ^d   Wei, Xiaoyu ^b   Zhang, Fujie ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (China)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CHINA; CLINICAL TRIAL; DRUG RESPONSE; DRUG TREATMENT FAILURE; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTERVIEW; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CHINA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 73649087653     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649215     Document Type: Article

References (37)

1. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Epidemiological fact sheet on HIV and AIDS, 2008 update. http://www.who.int/ globalatlas/predefinedReports/EFS2008/full/EFS2008-CN.pdf. Accessed 24 December 2008.
2. Xu JQ, Wang JJ, Han LF, et al. Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J (Engl) 2006;119:1941-1948.
3. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China's response to HIV/AIDS. Lancet 2007; 369:679-690.
4. Qian HZ, Vermund SH. Antiretroviral therapy for former plasma donors in China: saving lives when HIV prevention fails [editorial], Clin Infect Dis 2008:47:834-836.
5. Watts J. Sex, drugs, and HIV/AIDS in China. Lancet 2008; 371:103-104.
6. Zhang F, Haberer JE, Wang Y, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS 2007;21(suppl 8): S143-S148.
7. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009; 151: 241-251.
8. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector-progress report 2008. http://www.who.int/hiv/pub/towards-universal-access-report-2008.pdf. Accessed 4 May 2009.
9. World Health Organization. Task shifting: global recommendations and guidelines. Available at: http://www.who.int/healthsystems/TTR-TaskShifting.pdf. Accessed 2 December 2008.
10. 10. Samb B, Celletti F, Holloway J, Van Damme W, De Cock KM, Dybul M. Rapid expansion of the health workforce in response to the HIV epidemic. N Engl J Med 2007;357:2510-2514. (Pubitemid 350272794)
11. Zhang F, ed. National free HIV antiretroviral treatment handbook. 2nd ed. Beijing, China: People's Medical Publishing House, 2008.
12. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2006 revision, http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 30 April 2009.
13. Anand S, Fan VY, Zhang J, et al. China's human resources for health: quantity, quality, and distribution. Lancet 2008;372:1774-1781.
14. Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008;47:825-833.
15. Taylor WD, Bosch EG. The datafax project [abstract P-45], Controlled Clin Trials 1990; 11:296.
16. Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature 2008;455:609-611.
17. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008;22:1971-1977.
18. Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006;42:252-259.
19. Boileau C, Nguyen VK, Sylla M, et al. Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr 2008; 48: 476-484.
20. 20. Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 2005;40:324-328. (Pubitemid 41533073)
21. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003; 17(suppl 3):S5-S15.
22. 22. Tuboi SH, Brinkhof MW, Egger M, et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1 -infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007;45:52-59. (Pubitemid 46684443)
23. Fielding KL, Charalambous S, Stenson AL, et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 2008; 8:93.
24. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007; 196(suppl 3):S464-S468.
25. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial-Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-937.
26. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006;20:2051-2064.
27. Carr A, Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 2009;23:343-353.
28. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-2315.
29. Berenguer J, Gonzalez J, Ribera E, et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 2008;47:1083-1092.
30. Bisson GP, Rowh A, Weinstein R, Gaolathe T, Frank I, Gross R. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 2008;49:107-110.
31. 31. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782-793. (Pubitemid 44223102)
32. 32. Moore DM, Hogg RS, Yip B, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005;40:288-293. (Pubitemid 41533068)
33. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008;47:553-558.
34. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49: 454-462.
35. 35. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(suppl 2):1-13. (Pubitemid 352019085)
36. 36. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007;21:721-732. (Pubitemid 46568629)
37. Hosseinipour M, van Oosterhout JJ, Weigel R, et al. Resistance profile of patients failing first line ART in Malawi when using clinical and immunologic monitoring. In: Program and abstracts of the XVII International AIDS Conference. Geneva, Switzerland: International AIDS Society, 2008. Abstract TUAB0105.